Novo Nordisk's RNAi therapy receives FDA approval for rare genetic conditions and kidney disorders
TL;DR Summary
Novo Nordisk has received FDA approval for nedosiran, an RNAi therapy developed by Dicerna Pharmaceuticals, to treat primary hyperoxaluria type 1 (PH1), a rare kidney disease. Marketed as Rivfloza, the drug is expected to be available in early 2024 and is approved to lower urinary oxalate levels in adults and children aged 9 and older.
Topics:business#dicerna-pharmaceuticals#healthcare#kidney-disease#novo-nordisk#primary-hyperoxaluria-type-1#rnai-therapy
- Novo Nordisk secures FDA approval of RNAi therapy from $3.3B Dicerna takeover Endpoints News
- US FDA approves Novo Nordisk's therapy for rare genetic condition Reuters
- FDA OKs Another Injectable for Rare Kidney Disorder Medpage Today
- With FDA nod for rare disease drug Rivfloza, Novo Nordisk eyes showdown with Alnylam FiercePharma
- View Full Coverage on Google News
Reading Insights
Total Reads
0
Unique Readers
15
Time Saved
0 min
vs 1 min read
Condensed
63%
148 → 55 words
Want the full story? Read the original article
Read on Endpoints News